Laverock Therapeutics secures £13.5m seed expansion led by Calculus Capital to advance gene silencing platform.
Calculus Capital led the financing round alongside several institutional investors to support platform development and pipeline progression.
Laverock Therapeutics develops a gene silencing platform to create programmable advanced therapies for human applications. The firm commercialises the gene editing induced gene silencing technology.
Laverock Therapeutics has expanded its seed round to £13.5m in a financing led by Calculus Capital. Additional backing came from Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund, and Tekfen Ventures.
The capital will support the ongoing development of the GEiGS technology and advance the company pipeline in regenerative medicine and immuno-oncology. Key priorities include moving candidates through in vitro and in vivo validation, expanding laboratory facilities, and growing the headcount.
The business was founded in 2021 to commercialise gene editing induced gene silencing for human therapeutic applications.
From the founder
"GEiGS is already showing significant potential to transform the safety and efficacy of advanced therapies and we are excited that this new investment will allow us to progress towards pre-clinical candidate selection. We’re pleased to welcome such an experienced group of investors on board, bringing extensive sector expertise which will help us to grow as a company and accelerate the development of targeted, responsive treatments."
David Venables
CEO at Laverock Therapeutics
Investor perspective
"We are delighted to support Laverock and its exceptional management team, led by CEO David Venables, as the company embarks on its next phase of expansion, pioneering a new era of programmable advanced therapies. We backed David’s previous venture, Synpromics, which delivered an exceptional return for Calculus investors in 2019. Laverock’s ambitious plans hold tremendous potential for the healthcare sector, and we are excited to be part of the journey."
Elizabeth Klein
Investment Director, Calculus Capital
Use of funds
- 01Grow the team
- 02Fund research and development
- 03Build out infrastructure
Investors
Elizabeth Klein
Calculus Capital
Eli Lilly and Company
Mercia Ventures
Maven Capital Partners
Eos
UK Innovation & Science Seed Fund
Tekfen Ventures
Categories
About the company
Laverock Therapeutics
Laverock Therapeutics develops a gene silencing platform for programmable advanced therapies.